Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab plus chemoradiotherapy for recurrent or metastatic cervical cancer after prior standard treatment
ChiCTR2000034748Phase 2Not yet recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Jun 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in Cervical Cancer (CC), sponsored by Fudan University Shanghai Cancer Center. Primary endpoint: 2-year progression-free survival rate. Planned start Jun 2020; status: not yet recruiting.
02
Drugs
tislelizumab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR2000034748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000034748.